SCHEMBL6328296

SCHEMBL6328296

COC(=O)CCc1nc(-c2ccc[nH]2)no1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
LMNA P02545 3/20 0.45
ATM Q13315 1/20 0.45
MCL1 Q07820 1/20 0.43
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 2/20 0.41
MITF O75030 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4564362 0.79 HPGD (0.68) HPGDLMNAATMALDH1A1GAA
SCHEMBL6333033 0.75 LMNA (0.61) HPGDLMNAATMALDH1A1SMN1; SMN2
SCHEMBL6324441 0.74 HPGD (0.45) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6326392 0.74 MAPK1 (0.54) HPGDLMNAATMALDH1A1GAA
SCHEMBL6325140 0.73 LMNA (0.58) HPGDLMNAATMALDH1A1SMN1; SMN2
SCHEMBL6323754 0.73 HTT (0.67) HPGDLMNAATMALDH1A1GAA
SCHEMBL6326028 0.72 LMNA (0.57) HPGDLMNAATMALDH1A1SMN1; SMN2
SCHEMBL7829263 0.72 HPGD (0.46) HPGDLMNAATMALDH1A1GAA
SCHEMBL6323359 0.72 HPGD (0.43) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6334541 0.72 KMT2A (0.55) HPGDLMNAATML3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
CN-1568187-A 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof ICOS CORP (US) 2005-01-19 CN disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 HPGD 539/4885LMNA 448/4885ATM 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.